清胰汤治疗对急性胰腺炎患者Toll样受体4/核转录因子-κB信号通路的影响

Effect of Qingyi Decoction on toll-like receptor 4/nuclear factor-κB signaling pathway in patients with acute pancreatitis

  • 摘要:
    目的 探讨清胰汤灌肠治疗对急性胰腺炎(AP)患者Toll样受体(TLR)4/核转录因子(NF)-κB信号通路的影响。
    方法 选取100例轻症AP患者为研究对象, 并随机分为对照组50例和观察组50例。对照组予以西医常规疗法联合乌司他丁治疗,观察组在对照组的基础上予以清胰汤保留灌肠治疗。比较2组临床疗效、症状缓解情况、中医证候积分以及胰腺功能指标、炎症指标和TLR4 mRNA、NF-κB mRNA表达水平。
    结果 观察组临床有效率为92.00%, 高于对照组的76.00%, 差异有统计学意义(P < 0.05)。观察组的腹部胀痛缓解时间、首次排便时间、肠鸣音恢复时间和淀粉酶(AMS)恢复正常时间短于对照组,差异有统计学意义(P < 0.05)。治疗10 d后, 2组腹痛拒按、痞满燥实、恶心呕吐、小便短赤证候积分低于治疗前,且观察组低于治疗组,差异有统计学意义(P < 0.05)。治疗10 d后, 2组血清AMS、脂肪酶(LPS)水平低于治疗前,且观察组低于治疗组,差异有统计学意义(P < 0.05)。治疗10 d后, 2组血清肿瘤坏死因子(TNF)-α、髓样细胞触发受体(TREM)-1、微管相关蛋白1轻链3(MAP1-LC3)、细胞黏附分子(ICAM)-1水平低于治疗前,且观察组低于治疗组,差异有统计学意义(P < 0.05)。治疗10 d后, 2组TLR4 mRNA、NF-κB mRNA表达水平低于治疗前,且观察组低于治疗组,差异有统计学意义(P < 0.05)。
    结论 清胰汤可有效改善AP患者腹痛、腹胀等临床症状,抑制炎症反应,以及促进胰腺功能恢复,其机制可能与抑制TLR4/NF-κB信号通路有关。

     

    Abstract:
    Objective To investigate the effect of Qingyi Decoction enema on the toll-like receptor (TLR) 4/nuclear factor (NF)-κB signaling pathway in patients with acute pancreatitis (AP).
    Methods A total of 100 patients with mild AP were selected as the study objects, and randomly divided into control group (n=50) and observation group (n=50). The control group received conventional western medicine therapy combined with ulinastatin, while the observation group was treated with Qingyi Decoction retention enema on the basis of control group. Clinical efficacy, symptom relief, traditional Chinese medicine syndrome scores, pancreatic function indicators, inflammatory markers as well as TLR4 mRNA and NF-κB mRNA expression levels were compared between the two groups.
    Results The clinical effective rate in the observation group was 92.00% which was significantly higher than 76.00% in the control group (P < 0.05). The observation group had significantly shorter times for abdominal distension pain relief, first bowel movement, recovery of bowel sounds and normalization of amylase (AMS) levels compared to the control group (P < 0.05). After 10 days of treatment, both groups showed significantly lower scores for abdominal pain, tenderness, fullness, dryness, nausea, vomiting and short red urine syndrome compared to before treatment, with the observation group showing significantly lower scores than the control group (P < 0.05). After 10 days of treatment, serum AMS and lipase (LPS) levels were significantly lower in both groups compared to before treatment, with the observation group showing significantly lower levels than the control group (P < 0.05). After 10 days of treatment, serum tumor necrosis factor (TNF)-α, triggering receptor expressed on myeloid cells (TREM)-1, microtubule-associated protein 1 light chain 3 (MAP1-LC3) and intercellular adhesion molecule (ICAM)-1 levels were significantly lower in both groups compared to before treatment, with the observation group showing significantly lower levels than the control group (P < 0.05). After 10 days of treatment, TLR4 mRNA and NF-κB mRNA expression levels were significantly lower in both groups compared to before treatment, with the observation group showing significantly lower levels than the control group (P < 0.05).
    Conclusion Qingyi Decoction can effectively improve the clinical symptoms of AP patients such as abdominal pain andabdominal distension, inhibit inflammatory response, and promote the recovery of pancreatic function, which may be related to the inhibition of TLR4/NF-κB signaling pathway.

     

/

返回文章
返回